| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
The Johns Hopkins Oncology Center, Baltimore, Maryland 21205
Taxol, a novel antimicrotubule agent that enhances tubulin polymerization and microtubule stability, was administered to adults with refractory leukemias as a 24-h i.v. infusion in a Phase I study. The primary objectives were to determine the maximum tolerated dose of taxol administered on this schedule to patients with acute leukemias and describe the nonhematological toxicities which became dose limiting. The starting dose, 200 mg/m2, was based on the maximum tolerated dose in solid tumor trials, in which myelosuppression precluded dose escalation. Seventeen patients received 28 evaluable courses at 200, 250, 315, and 390 mg/m2. Severe mucositis limited further dose escalation. Other nonhematological effects included peripheral neuropathy, alopecia, myalgias, arthralgias, nausea, vomiting, diarrhea, and an acute pulmonary reaction that was presumptively due to taxol's Cremophor vehicle.
Mean peak taxol plasma concentrations at all dose levels were in the range of concentrations that were previously demonstrated to induce microtubule bundles, a morphological effect associated with cytotoxicity, in leukemia cells in vitro. Pretreatment blasts from 12 patients were incubated with taxol ex vivo. Taxol-induced microtubule bundles were apparent in the blasts of eight patients who also had cytoreduction of tumor, and sensitivity to bundle formation was related to the magnitude of antitumor activity. In contrast, taxol did not induce microtubule bundles ex vivo in the blasts of the other four total nonresponders.
Based on this study, the maximum tolerated doses and recommended Phase II doses for taxol, limited by nonhematological toxicity and administered as a 24-h i.v. infusion to patients with refractory leukemias, are 390 and 315 mg/m2. Phase II trials at these myelosuppressive doses are required to determine taxol's activity in the treatment of leukemias. In addition, further evaluation of microtubule bundle formation ex vivo in Phase II studies is necessary to determine the ultimate utility of this assay in assessing tumor sensitivity to taxol.
1 Supported in part by National Cancer Institute Contract NCI-CM 57738. Presented in part at the annual meeting of the American Association for Cancer Research, New Orleans, LA, May 1988.
2 Recipient of an American Cancer Society Career Development Award. To whom requests for reprints should be addressed, at The Johns Hopkins Oncology Center, Pharmacology Laboratory, Rm 1-121, 600 North Wolfe Street, Baltimore, MD 21205.
Received 12/27/88. Revised 5/ 4/89. Accepted 5/10/89.
This article has been cited by other articles:
|
|
 |
|
  S. H. Zhuang, Y. E. Hung, L. Hung, R. W. Robey, D. L. Sackett, W. M. Linehan, S. E. Bates, T. Fojo, and M. S. Poruchynsky Evidence for Microtubule Target Engagement in Tumors of Patients Receiving Ixabepilone Clin. Cancer Res., December 15, 2007; 13(24): 7480 - 7486. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Johnson, D. M. Lucas, N. Muthusamy, L. L. Smith, R. B. Edwards, M. D. De Lay, C. M. Croce, M. R. Grever, and J. C. Byrd Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia Blood, August 15, 2006; 108(4): 1334 - 1338. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Joerger, A. D.R. Huitema, D. H.J.G. van den Bongard, J. H.M. Schellens, and J. H. Beijnen Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of Paclitaxel in patients with solid tumors. Clin. Cancer Res., April 1, 2006; 12(7 Pt 1): 2150 - 2157. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Kikuno, N. Moriyama-Gonda, T. Yoshino, T. Yoneda, S. Urakami, M. Terashima, M. Yoshida, H. Kishi, K. Shigeno, H. Shiina, et al. Blockade of Paclitaxel-Induced Thymidine Phosphorylase Expression Can Accelerate Apoptosis in Human Prostate Cancer Cells Cancer Res., October 15, 2004; 64(20): 7526 - 7532. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. G. Ziske, B. Schottker, M. Gorschluter, U. Mey, R. Kleinschmidt, U. Schlegel, T. Sauerbruch, and I. G. H. Schmidt-Wolf Acute transient encephalopathy after paclitaxel infusion: report of three cases Ann. Onc., April 1, 2002; 13(4): 629 - 631. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Curtin, J. A. Blessing, K. D. Webster, P. G. Rose, A. R. Mayer, W. C. Fowler Jr, J. H. Malfetano, and R. D. Alvarez Paclitaxel, an Active Agent in Nonsquamous Carcinomas of the Uterine Cervix: A Gynecologic Oncology Group Study J. Clin. Oncol., March 1, 2001; 19(5): 1275 - 1278. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Schilder, J. M. Gallo, M. M. Millenson, M. A. Bookman, L. M. Weiner, A. Rogatko, B. Rogers, K. Padavic-Shallers, M. Boente, N. Rosenblum, et al. Phase I Trial of Multiple Cycles of High-Dose Carboplatin, Paclitaxel, and Topotecan With Peripheral-Blood Stem-Cell Support as Front-Line Therapy J. Clin. Oncol., February 15, 2001; 19(4): 1183 - 1194. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. F. Bishop, J. Dewar, G. C. Toner, J. Smith, M. H.N. Tattersall, I. N. Olver, S. Ackland, I. Kennedy, D. Goldstein, H. Gurney, et al. Initial Paclitaxel Improves Outcome Compared With CMFP Combination Chemotherapy as Front-Line Therapy in Untreated Metastatic Breast Cancer J. Clin. Oncol., August 1, 1999; 17(8): 2355 - 2355. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. K. Rowinsky, M. Jiroutek, P. Bonomi, D. Johnson, and S. D. Baker Paclitaxel Steady-State Plasma Concentration as a Determinant of Disease Outcome and Toxicity in Lung Cancer Patients Treated with Paclitaxel and Cisplatin Clin. Cancer Res., April 1, 1999; 5(4): 767 - 774. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J Medina, R. S DiPaola, and S. Goodin Treatment of hormone-refractory prostate cancer Journal of Oncology Pharmacy Practice, March 1, 1999; 5(1): 32 - 48. [Abstract] [PDF]
|
|
|
|
|
|
E. K. Rowinsky On Pushing the Outer Edge of the Outer Edge of Paclitaxel's Dosing Envelope Clin. Cancer Res., March 1, 1999; 5(3): 481 - 486. [Full Text] [PDF]
|
|
|
|
|
|
Y. Nieto, P. J. Cagnoni, S. I. Bearman, E. J. Shpall, S. Matthes, T. DeBoom, A. Baron, and R. B. Jones Acute Encephalopathy: A New Toxicity Associated with High-Dose Paclitaxel Clin. Cancer Res., March 1, 1999; 5(3): 501 - 506. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Woo, M. V. Relling, D. S. Sonnichsen, G. K. Rivera, C. B. Pratt, C.-H. Pui, W. E. Evans, and A. S. Pappo Phase I Targeted Systemic Exposure Study of Paclitaxel in Children with Refractory Acute Leukemias Clin. Cancer Res., March 1, 1999; 5(3): 543 - 549. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. F. Lam, C. J. Chan, and J. G Kuhn Review : Pharmacokinetics and pharmacodynamics of the taxanes Journal of Oncology Pharmacy Practice, June 1, 1997; 3(2): 76 - 93. [Abstract] [PDF]
|
|
|
|
 |
|
 E. K. Rowinsky and R. C. Donehower Paclitaxel (Taxol) N. Engl. J. Med., April 13, 1995; 332(15): 1004 - 1014. [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Betcher and N. Burnham Taxol Journal of Pediatric Oncology Nursing, January 1, 1993; 10(1): 37 - 39. [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
